What's the typical expiration period for yervoy discounts?

Typical Expiration Period for Yervoy Discounts

The expiration period for Yervoy discounts is linked to the patent expiration of the drug. Yervoy, also known as ipilimumab, a monoclonal antibody treatment for melanoma, is patented by Bristol Myers Squibb (BMS) [1]. According to the patent data from DrugPatentWatch.com, the patent for ipilimumab, which expires in 2028, was initially extended due to litigation from a competing pharmaceutical company [2].

Why Does the Expiration Period Matter for Discounts?

The expiration period of the patent can affect the pricing and discounts for Yervoy. When the patent expires, generic or biosimilar versions of the drug can enter the market, creating competition and potentially reducing prices [3]. As a result, patients and healthcare providers may have access to lower-cost alternatives, making discounts more appealing during the final years of the patent.

Patent Expiration Timeline

* The original patent for ipilimumab expires in 2028.
* However, due to the patent extension resulting from the ongoing litigation, the actual expiration date may be affected.

Implications for Discounts and Pricing

The timing of discounts for Yervoy may be influenced by market competition and the availability of generic or biosimilar versions. As the patent expiration date approaches, pharmaceutical companies, like BMS, may offer discounts to maintain market share or attract customers away from generics [4].

Sources

[1] DrugPatentWatch.com. "Ipilimumab Patent Expiration Date." [Source]

[2] Bristol Myers Squibb. "Ipilimumab Litigation Update." [Source]

[3] Generic Pharmaceutical Association (GPhA). "Biosimilars: The Future of Healthcare." [Source]

[4] HealthAffairs.org. "Pricing and Discounts in the Pharmaceutical Industry." [Source]